In the evolving landscape of cardiometabolic health, the demand for high-quality, reliable data in obesity trials remains critical to successful therapeutic development. By combining strategic recruitment strategies with a streamlined operational model, DelRicht Research continues to set the standard for clinical excellence in the cardiometabolic space.

Surpassing Enrollment Goals

The U.S. based Phase 2b trial evaluated the efficacy and safety of novel therapeutic interventions over a 74-week duration in adults ≥18 years old with overweight or obesity. To qualify, participants were required to present with at least one weight-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, or obstructive sleep apnea), while excluding individuals with type 2 diabetes, recent significant body weight fluctuations, or a history of surgical weight-loss interventions.

The study had an overall enrollment goal of 872 participants across 65 sites. DelRicht Research was entrusted with enrolling participants across seven sites:

●  Dr. Kymberly Moyer | Hendersonville, TN
●  Dr. Taylor Sanders | Prairieville, LA
●  Dr. Luke Van Kirk | Springfield, MO
●  Dr. Olabisi Badmus | Charlotte, NC
●  Dr. Jennifer Zomnir | Dallas, TX
●  Dr. Vijayendra Jaligam | Vienna, VA
●  Dr. Rachael Murphy | Mandeville, LA

DelRicht’s participating sites averaged a rapid 2.6 day activation to screening timeline, creating early enrollment momentum. Over the 3-month enrollment period, our network enrolled 228 participants, achieving 243.1% of the expected enrollment goal. Marshall Morris, Partner at DelRicht Research commented:

“Outperforming industry enrollment benchmarks across seven sites demonstrates how an experienced, embedded research network turns protocol challenges into predictable execution, ultimately de-risking development timelines for sponsors in obesity trials.” – Marshall Morris, Partner at DelRicht Research

Navigating Study Challenges

The trial’s strict eligibility criteria and long-term commitment presented unique operational challenges during execution:

1.  Eligibility Criteria: The patient pool was narrowed by the required verification of sustained weight stability, comorbidities, diabetes exclusions, and medication washouts.

2.  Patient Burden: The long-term treatment duration and required visit frequency demanded extensive patient commitment involving dual injections, fasting labs, 24-hour Holter monitoring, ongoing safety tracking, and side-effect management.

Despite these hurdles, all seven DelRicht sites implemented proactive strategies to streamline execution, maintain high-volume enrollment, and ensure long-term patient engagement. Sites supported trial success through:

1. Targeted Recruitment: Sites identified qualifying patients through established referral networks and prescreened medical records to streamline recruitment.

2. Patient-Centered Support: Deployment of dedicated coordinators, proactive side-effect education, automated ePRO reminders, and consolidated visit assessments minimized patient burden and ensured quality data capture.

What This Means for Sponsors and CROs

This study reinforces several key takeaways for sponsors and CROs navigating complex metabolic trials:

●  Rapid activation to screening timelines can significantly accelerate overall study progress when paired with strong internal coordination.

●  Patient-centered retention strategies that educate and highlight participation benefits ensure reliable engagement in long-term obesity trials.

●  Sites that combine operational rigor with proactive planning consistently outperform expectations.

Your Partner in Obesity Research

By combining rapid screening timelines, proactive patient management, and robust infrastructure, DelRicht Research continues to demonstrate how high-performing site networks can de-risk clinical development and accelerate time to market for innovative therapies.

To learn more about partnering with DelRicht Research for upcoming clinical programs in obesity, metabolic disorders, and general medicine, visit www.delrichtresearch.com or contact our business development team.